[go: up one dir, main page]

MX380238B - Anticuerpos especificos para mmp9. - Google Patents

Anticuerpos especificos para mmp9.

Info

Publication number
MX380238B
MX380238B MX2017001959A MX2017001959A MX380238B MX 380238 B MX380238 B MX 380238B MX 2017001959 A MX2017001959 A MX 2017001959A MX 2017001959 A MX2017001959 A MX 2017001959A MX 380238 B MX380238 B MX 380238B
Authority
MX
Mexico
Prior art keywords
mmp9
specific antibodies
fragment
useful
chain variable
Prior art date
Application number
MX2017001959A
Other languages
English (en)
Other versions
MX2017001959A (es
Inventor
Christine Power
Kinsey Maundrell
Laurence Goffin
Olivier Leger
Steven M Dunn
Missotten Yolande Chvatchko
Original Assignee
Ea Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ea Pharma Co Ltd filed Critical Ea Pharma Co Ltd
Publication of MX2017001959A publication Critical patent/MX2017001959A/es
Publication of MX380238B publication Critical patent/MX380238B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)

Abstract

La presente invención se refiere a nuevas proteínas que se unen a MMP9 y comprenden al menos un fragmento de una región variable de cadena pesada y/o al menos un fragmento de una región variable de cadena ligera de un anticuerpo. En particular, las proteínas de unión a MMP9 de acuerdo con la invención son capaces de neutralizar la actividad de MMP9, y son útiles en la prevención y/o tratamiento de enfermedades o cánceres inflamatorios y/o autoinmunes. En particular, las proteínas de unión a MMP9 de acuerdo con la invención son útiles en el diagnóstico de trastornos relacionados con MMP9.
MX2017001959A 2014-08-13 2015-08-13 Anticuerpos especificos para mmp9. MX380238B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14180765.1A EP2985296A1 (en) 2014-08-13 2014-08-13 Antibodies specific for MMP9
PCT/EP2015/068645 WO2016023979A1 (en) 2014-08-13 2015-08-13 Antibodies specific for mmp9

Publications (2)

Publication Number Publication Date
MX2017001959A MX2017001959A (es) 2017-05-04
MX380238B true MX380238B (es) 2025-03-12

Family

ID=51301193

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001959A MX380238B (es) 2014-08-13 2015-08-13 Anticuerpos especificos para mmp9.

Country Status (13)

Country Link
US (1) US10364296B2 (es)
EP (2) EP2985296A1 (es)
JP (1) JP6856523B2 (es)
KR (1) KR20170041222A (es)
CN (1) CN106573984A (es)
AU (1) AU2015303183B2 (es)
BR (1) BR112017002703A2 (es)
CA (1) CA2956986A1 (es)
ES (1) ES2784271T3 (es)
MX (1) MX380238B (es)
PL (1) PL3180362T3 (es)
RU (1) RU2714043C2 (es)
WO (1) WO2016023979A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3440113A1 (en) 2016-04-08 2019-02-13 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
WO2018109222A1 (en) 2016-12-16 2018-06-21 Universite de Bordeaux Mmp9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder
TWI825021B (zh) 2017-06-02 2023-12-11 德商麥克專利有限公司 與ｍｍｐ１３結合之免疫球蛋白
KR102596374B1 (ko) * 2017-06-30 2023-10-30 고쿠리츠 켄큐 카이하츠 호진 이야쿠 키반 켄코 에이요 켄큐쇼 대장암을 검출하기 위한 바이오마커
JP7109440B2 (ja) 2017-07-18 2022-07-29 第一三共株式会社 活性型ｍｍｐ－９結合ペプチド
JP2021506763A (ja) 2017-12-13 2021-02-22 ノース カロライナ ステート ユニバーシティＮｏｒｔｈ Ｃａｒｏｌｉｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ 化学療法剤とチェックポイント阻害剤とを含む組成物及び使用の方法
DK3743534T3 (da) * 2018-01-22 2022-06-20 Liquid Biopsy Res Llc Fremgangsmåde til påvisning af coloncancer og behandlingsovervågning
CN108277214B (zh) * 2018-02-23 2021-07-06 广东医科大学 一种应激磷酸化抗原多肽、抗体、制备方法以及应用
EP3972644A4 (en) * 2019-05-21 2024-01-10 The Regents Of The University Of California MMP-9 ANTIBODIES AND METHODS OF USE THEREOF
CN110885375B (zh) * 2019-12-20 2021-07-02 南京融捷康生物科技有限公司 特异性针对mmp-9蛋白锌离子结合结构域的单域抗体及产品与应用
WO2023278491A1 (en) * 2021-06-28 2023-01-05 Releviate, Llc Mmp-9 antibodies and uses thereof
CN117327186B (zh) * 2023-07-12 2024-03-12 北京达成生物科技有限公司 结合mmp3蛋白的双特异性抗体及其用途
CN117264069B (zh) * 2023-11-23 2024-01-26 再少年(北京)生物科技有限公司 一种促进皮肤组织再生的工程化外泌体的制备方法及其应用
CN117820488B (zh) * 2024-01-09 2024-10-01 首都医科大学附属北京朝阳医院 特异性针对mmp-9的抗体对、生物材料及其应用
CN117964771B (zh) * 2024-04-02 2024-06-21 智泽童康(广州)生物科技有限公司 一种特异性结合mmp7的抗体、mmp7检测试剂及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002235692A1 (en) * 2001-02-23 2002-09-04 Biophage Inc. Methods and compositions for preventing and treating neutrophil-mediated diseases
GB0516069D0 (en) 2005-08-04 2005-09-14 Imp College Innovations Ltd Pharmaceutical and use thereof
CN101702906B (zh) * 2007-02-23 2014-02-12 耶达研究及发展有限公司 用于抑制金属蛋白活性的抗体和含有所述抗体的药物组合物
WO2009111450A2 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 binding proteins
US8013125B2 (en) 2008-03-03 2011-09-06 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
WO2010045388A2 (en) * 2008-10-14 2010-04-22 Dyax Corp. Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
US20110135573A1 (en) 2009-09-03 2011-06-09 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
KR101518144B1 (ko) * 2010-08-27 2015-05-28 길리아드 바이오로직스, 인크. 매트릭스 메탈로프로테이나제 ９에 대한 항체
BR112014021477A2 (pt) 2012-02-29 2018-06-12 Gilead Sciences Inc anticorpos para metaloproteinase de matriz 9
MY167236A (en) * 2012-02-29 2018-08-14 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9

Also Published As

Publication number Publication date
JP2017532005A (ja) 2017-11-02
WO2016023979A1 (en) 2016-02-18
EP2985296A1 (en) 2016-02-17
EP3180362A1 (en) 2017-06-21
RU2017107773A (ru) 2018-09-13
US20170233495A1 (en) 2017-08-17
BR112017002703A2 (pt) 2018-02-27
EP3180362B1 (en) 2020-02-05
MX2017001959A (es) 2017-05-04
RU2017107773A3 (es) 2018-09-13
CN106573984A (zh) 2017-04-19
PL3180362T3 (pl) 2020-06-15
KR20170041222A (ko) 2017-04-14
RU2714043C2 (ru) 2020-02-11
ES2784271T3 (es) 2020-09-23
CA2956986A1 (en) 2016-02-18
AU2015303183B2 (en) 2021-01-28
JP6856523B2 (ja) 2021-04-07
AU2015303183A1 (en) 2017-02-16
US10364296B2 (en) 2019-07-30

Similar Documents

Publication Publication Date Title
MX2017001959A (es) Anticuerpos especificos para mmp9.
CY1121893T1 (el) Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων
CY1121542T1 (el) Μορια αντισωματων σε pd-1 και χρηση αυτων
CY1125267T1 (el) Antiσωmata eiδiκως σynδeonta pd-1 kai xphσeiς aytωn
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
SA522431756B1 (ar) Tigit أجسام مضادة لـ
EA202091540A1 (ru) Антитела к lilrb2
EA201790834A1 (ru) Молекулы антител к pd-l1 и их применение
EA201990594A1 (ru) Анти-tim-3 антитела и их применение
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
CR20190550A (es) Anticuerpos que se unen específicamente a pd-1 y métodos de uso
EA201791093A1 (ru) Антитела к cd47, способы и применение
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
MX375032B (es) Proteínas de unión y métodos para utilizarlas.
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
EA202091315A3 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
CY1124445T1 (el) Αντισωματα αντι-ccl17
PH12019500342A1 (en) Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6
MX2017007747A (es) Anticuerpos para il-17c.
EA201691414A1 (ru) Антитела к матриксной металлопротеиназе 9 и способы их применения
MX2018004228A (es) Anticuerpo que se une especificamente a erbb3 y uso de este.